Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") 1992

J A Henry, and K J Jeffreys, and S Dawling
National Poisons Unit, Guy's Hospital, London, UK.

The risk of adverse reactions to 3,4-methylenedioxymethamphetamine (MDMA), more commonly known as "ecstasy", is now widely known in both the USA and UK, but the patterns of illness remain varied. We report our experience during 1990 and 1991. There has been a recent increase in cases of severe toxicity following recreational misuse of small amounts of MDMA. Among 7 fatalities, the pattern of toxicity included fulminant hyperthermia, convulsions, disseminated intravascular coagulation, rhabdomyolysis, and acute renal failure. Until now, there have been few reports of this type of toxicity from MDMA, which may be related both to the potential of the drug to alter thermoregulation and to the circumstances of misuse. In addition, we have monitored 7 cases of hepatotoxicity and suspect that the frequency of this complication is increasing; a history of MDMA misuse should be sought in young people presenting with unexplained jaundice or hepatomegaly. We also describe 5 subjects involved in road traffic accidents in whom MDMA was identified. Misuse of MDMA can have severe acute toxic effects; few data are available concerning long-term morbidity, and this deserves close monitoring in future.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D009017 Morbidity The proportion of patients with a particular disease during a given year per given unit of population. Morbidities
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015104 3,4-Methylenedioxyamphetamine An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. 3,4 Methylenedioxyamphetamine
D018817 N-Methyl-3,4-methylenedioxyamphetamine An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. MDMA,Methylenedioxymethamphetamine,Ecstasy (Drug),N-Methyl-3,4-methylenedioxyamphetamine Hydrochloride,Hydrochloride, N-Methyl-3,4-methylenedioxyamphetamine,N Methyl 3,4 methylenedioxyamphetamine,N Methyl 3,4 methylenedioxyamphetamine Hydrochloride
D019966 Substance-Related Disorders Disorders related to substance use or abuse. Chemical Dependence,Drug Abuse,Drug Addiction,Drug Dependence,Drug Habituation,Drug Use Disorder,Drug Use Disorders,Organic Mental Disorders, Substance-Induced,Substance Abuse,Substance Dependence,Substance Related Disorder,Substance Use,Substance Use Disorder,Substance Use Disorders,Prescription Drug Abuse,Substance Addiction,Abuse, Drug,Abuse, Prescription Drug,Abuse, Substance,Addiction, Drug,Addiction, Substance,Chemical Dependences,Dependence, Chemical,Dependence, Drug,Dependence, Substance,Dependences, Chemical,Disorder, Drug Use,Disorder, Substance Related,Disorder, Substance Use,Disorders, Substance Related,Drug Abuse, Prescription,Habituation, Drug,Organic Mental Disorders, Substance Induced,Related Disorder, Substance,Related Disorders, Substance,Substance Abuses,Substance Uses,Use, Substance

Related Publications

J A Henry, and K J Jeffreys, and S Dawling
March 2003, The American journal of emergency medicine,
J A Henry, and K J Jeffreys, and S Dawling
February 1998, Acta crystallographica. Section C, Crystal structure communications,
J A Henry, and K J Jeffreys, and S Dawling
April 2004, Therapeutic drug monitoring,
J A Henry, and K J Jeffreys, and S Dawling
January 1996, Journal of the Royal Society of Medicine,
J A Henry, and K J Jeffreys, and S Dawling
January 2022, Current research in toxicology,
J A Henry, and K J Jeffreys, and S Dawling
October 2010, Clinical toxicology (Philadelphia, Pa.),
J A Henry, and K J Jeffreys, and S Dawling
January 1999, The Journal of the American Board of Family Practice,
J A Henry, and K J Jeffreys, and S Dawling
November 2001, Journal of forensic sciences,
J A Henry, and K J Jeffreys, and S Dawling
July 2021, European journal of pharmacology,
Copied contents to your clipboard!